Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Yian Zhang, Bingzong Li, Junling Zhuang, Pengcheng He, Xingli Zhao, Baijun Fang, Songfu Jiang, Bing Chen, Zhongjun Xia, Zhenyu Li, Zengjun Li, Haifeng Zhao, Dawei Ding, Qianqian Zhang, Xunqiang Wang, Peng Liu

Blood (2025) 146 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2025-2279

Published: 2025

Journal Articles

GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)

Chengcheng Fu, Xuhong Fu, Bing Chen, Qingsong Yin, Songfu Jiang, Jingjing Shang, Chaoyang Guan, Song Jin, Yingying Zhai, Xiuyi Song, Xiaobao Yang, Depei Wu

Blood (2025) 146 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2025-2278

Published: 2025

Journal Articles

Clinical and experimental characteristics of a hereditary thrombocythemia family with co-mutation in JAK2 involving ferm and pseudo-kinase domains

Qiguo Zhang, Yuyan Zhang, Wenjing Fu, Chun Ling, Wenqiang Bao, Qichuan Jin, Bing Chen

Blood (2025) 146 (Supplement 1): 7326.

https://doi.org/10.1182/blood-2025-7326

Published: 2025

Journal Articles

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Bing Chen, Xiaoyan Shao, Yuanyuan Jin, Yong Xu, Qinglin Shi, Chaoyang Guan, Xuxing Shen, Ping Li, Yujie Wu, Hui Zeng, Yu Zhu, Min Zhou, Lei Fan, Yaqiong Lu, Hongyu Gui, Lijuan Chen

Blood (2025) 146 (Supplement 1): 254.

https://doi.org/10.1182/blood-2025-254

Published: 2025

Journal Articles

Mednext-based automatic segmentation of 18F-FDG PET images in angioimmunoblastic T-cell lymphoma and prognostic value exploration of predicted Total metabolic tumor volume

xinyuan chen, Bing Chen, Jingyan Xu

Blood (2025) 146 (Supplement 1): 7168.

https://doi.org/10.1182/blood-2025-7168

Published: 2025

Journal Articles

The total blood n-glycome landscape of hematological malignancies

Yueyi Xu, Jue Wang, Junli Zhang, Cuiying Chen, Huang Hongming, Xiaofeng Shi, Xuejun Zhu, Xuezhong Zhang, Jinning Shi, Xiaogang Zhou, Jiahua Ding, Bing Chen, Jian Ouyang

Blood (2025) 146 (Supplement 1): 391.

https://doi.org/10.1182/blood-2025-391

Published: 2025

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Wei-Bin Wu, Ya-Wen Luo, Siqi Li, Lanping Xu, Yu Wang, Xiaohui Zhang, Yuqian Sun, Feifei Tang, Xiaodong Mo, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, He-Bing Chen, Ying-Jun Chang, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2024-207920

Published: 2024

Journal Articles

A Novel Engineering Platelet Platform Target the Macrophages to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis

Zhenyu Liu, Ying Du, Rongfu Zhou, Bing Chen, Peipei Xu

Blood (2024) 144 (Supplement 1): 1146.

https://doi.org/10.1182/blood-2024-206792

Published: 2024

Journal Articles

Study on Clinical and Laboratory Characteristics of Acute Erythroid Leukemia with EPOR Amplification

Wenjing Fu, Qiguo Zhang, Wenyu Gong, Wenqiang Bao, Shiyun Xu, Chun Ling, Qichuan Jin, Bing Chen

Blood (2024) 144 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2024-194478

Published: 2024

Journal Articles

Diagnostic Challenges in the Leukemia Phase of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Involvement: A Clinical and Pathological Study

Qiguo Zhang, Wenjing Fu, Wenqiang Bao, Chun Ling, Qichuan Jin, Bing Chen

Blood (2023) 142 (Supplement 1): 5983.

https://doi.org/10.1182/blood-2023-172700

Published: 2023

Journal Articles

Human Single Domain Antibody-Based CAR-T Cells Targeting BAFF-R Demonstrate Promising Preclinical Activity in B Cell Malignancies

Cuiling Zhang, Qian Luo, Sungui Wu, Le Xu, Qiaoe Wei, Yanying Zhang, Chaoyang Guan, Xiaoqing Dong, Taochao Tan, Bing Chen

Blood (2023) 142 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2023-181372

Published: 2023

Journal Articles

PET Radiomics Score Generated By Cross-Combination Approach for Treatment Response and Prognosis Prediction in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma Patients

Jincheng Zhao, Jian Rong, Yue Teng, Man Chen, Bing Chen, Chong Jiang, Jianxin Chen, Jingyan Xu

Blood (2023) 142 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2023-177538

Published: 2023

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li, Lu-Gui Qiu, Di Wang, Yongping Song, He Huang, Jianyong Li, Bing Chen, Jing Liu, Yujun Dong, Kai Hu, Peng Liu, Xi Zhang, Jianqing Mi, Zhenyu Li, Kaiyang Ding, Shiyue Zhang, Guang Hu, Wen Wang

Blood (2023) 142 (Supplement 1): 761.

https://doi.org/10.1182/blood-2023-173427

Published: 2023

Journal Articles

Congenital Factor VII Deficiency : A Retrospective Analysis of 14 Cases from One Hospital

Rongfu Zhou, Mao Xia, Yanhui Yuan, Xiaoyan Shao, Yuyi Xu, Bing Chen

Blood (2023) 142 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2023-186679

Published: 2023

Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7435–7436.

https://doi.org/10.1182/blood-2022-166465

Published: 2022

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

PRMT5 Regulates Cell Pyroptosis By Silencing CASP1 in Multiple Myeloma

Tian Xia, Ming Liu, Quan Zhao, Rongfu Zhou, Bing Chen, Peipei Xu

Blood (2021) 138 (Supplement 1): 4710.

https://doi.org/10.1182/blood-2021-147092

Published: 2021

Journal Articles

Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China

Blood (2019) 134 (Supplement_1): 3181.

https://doi.org/10.1182/blood-2019-128614

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)

Clinical and experimental characteristics of a hereditary thrombocythemia family with co-mutation in JAK2 involving ferm and pseudo-kinase domains

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Mednext-based automatic segmentation of 18F-FDG PET images in angioimmunoblastic T-cell lymphoma and prognostic value exploration of predicted Total metabolic tumor volume

The total blood n-glycome landscape of hematological malignancies

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

A Novel Engineering Platelet Platform Target the Macrophages to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis

Study on Clinical and Laboratory Characteristics of Acute Erythroid Leukemia with EPOR Amplification

Diagnostic Challenges in the Leukemia Phase of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Involvement: A Clinical and Pathological Study

Human Single Domain Antibody-Based CAR-T Cells Targeting BAFF-R Demonstrate Promising Preclinical Activity in B Cell Malignancies

PET Radiomics Score Generated By Cross-Combination Approach for Treatment Response and Prognosis Prediction in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma Patients

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Congenital Factor VII Deficiency : A Retrospective Analysis of 14 Cases from One Hospital

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

PRMT5 Regulates Cell Pyroptosis By Silencing CASP1 in Multiple Myeloma

Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only